NCT00436748

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

FDA and EMA agreed that the information that had been submitted to date was acceptable to meet the requirements of the post-marketing commitment.